- Home
- AU vs ROIV Comparison
AU vs ROIV Comparison
Compare AU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- ROIV
- Stock Information
- Founded
- AU 1944
- ROIV 2014
- Country
- AU United States
- ROIV United Kingdom
- Employees
- AU N/A
- ROIV N/A
- Industry
- AU Precious Metals
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AU Basic Materials
- ROIV Health Care
- Exchange
- AU Nasdaq
- ROIV Nasdaq
- Market Cap
- AU 30.2B
- ROIV 8.6B
- IPO Year
- AU 1972
- ROIV N/A
- Fundamental
- Price
- AU $64.52
- ROIV $15.28
- Analyst Decision
- AU Buy
- ROIV Strong Buy
- Analyst Count
- AU 5
- ROIV 4
- Target Price
- AU $47.30
- ROIV $15.50
- AVG Volume (30 Days)
- AU 3.3M
- ROIV 7.8M
- Earning Date
- AU 11-06-2025
- ROIV 11-11-2025
- Dividend Yield
- AU 1.43%
- ROIV N/A
- EPS Growth
- AU 1303.37
- ROIV N/A
- EPS
- AU 3.81
- ROIV N/A
- Revenue
- AU $7,649,000,000.00
- ROIV $23,233,000.00
- Revenue This Year
- AU $62.30
- ROIV N/A
- Revenue Next Year
- AU N/A
- ROIV $281.14
- P/E Ratio
- AU $17.23
- ROIV N/A
- Revenue Growth
- AU 54.59
- ROIV N/A
- 52 Week Low
- AU $22.45
- ROIV $8.73
- 52 Week High
- AU $67.67
- ROIV $16.05
- Technical
- Relative Strength Index (RSI)
- AU 66.81
- ROIV 82.00
- Support Level
- AU $56.68
- ROIV $13.81
- Resistance Level
- AU $67.67
- ROIV $14.48
- Average True Range (ATR)
- AU 1.90
- ROIV 0.47
- MACD
- AU 0.48
- ROIV 0.22
- Stochastic Oscillator
- AU 76.24
- ROIV 81.67
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.